A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.
NCT00752505
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Subjects who have a recognised diagnosis of fibromyalgia, with defined minimum pain criteria. Control subjects must not have a fibromyalgia diagnosis or symptoms and must match fibromyalgia subjects for age, length of education and gender
- Other confounding pain, cognitive disease or impairment, disease that could put the
subject at risk or subjects who are on prohibited medications that cannot be washed
out.
- Any subjects with a diagnosis of certain psychiatric disorders in particular major
depression or suicidal risk. Matched control subjects have similar exclusions.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Newton, Massachusetts
- Beverly Hills, California
- Beverly Hills, California
- Huntington Beach, California
- Tucson, California
- West Hills, California
- Tempe, Arizona
- Birmingham, Alabama
- Birmingham, Alabama
- Huntsville, Alabama
- Phoenix, Arizona
- Phoenix, Arizona
- Scottsdale, Arizona
- Hot Springs, Arkansas
- Little Rock, Arkansas
- Beverly Hills, California
- Los Alamitos, California
- Newport Beach, California
- Northridge, California
- Pismo Beach, California
- Redondo Beach, California
- Riverside, California
- Walnut Creek, California
- Whittier, California
- Danbury, Connecticut
- New Milford, Connecticut
- Stratford, Connecticut
- Clearwater, Florida
- Miami, Florida
- Ocala, Florida
- Palm Beach Gardens, Florida
- Seminole, Florida
- St. Petersburg, Florida
- St. Petersburg, Florida
- St. Petersburg, Florida
- Sunrise, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Decatur, Georgia
- Boise, Idaho
- Chicago, Illinois
- Maywood, Illinois
- Oak Brook, Illinois
- Peoria, Illinois
- Kansas City, Kansas
- Overland Park, Kansas
- Madisonville, Kentucky
- New Orleans, Louisiana
- Newton, Massachusetts
- Kalamazoo, Michigan
- Lansing, Michigan
- Kansas City, Missouri
- Lebanon, New Hampshire
- Princeton, New Jersey
- Albany, New York
- New York, New York
- Rochester, New York
- Charlotte, North Carolina
- Wilmington, North Carolina
- Wilmington, North Carolina
- Winston Salem, North Carolina
- Winston-Salem, North Carolina
- Cincinnati, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Mogadore, Ohio
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Eugene, Oregon
- Medford, Oregon
- Portland, Oregon
- Altoona, Pennsylvania
- Duncansville, Pennsylvania
- Johnstown, Pennsylvania
- Mechanicsburg, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pottstown, Pennsylvania
- West Reading, Pennsylvania
- Wyomissing, Pennsylvania
- Anderson, South Carolina
- Charleston, South Carolina
- Greer, South Carolina
- Memphis, Tennessee
- Memphis, Tennessee
- Nashville, Tennessee
- Austin, Texas
- Dallas, Texas
- Lubbock, Texas
- Richardson, Texas
- San Antonio, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Woodstock, Vermont
- Virginia Beach, Virginia
- Seattle, Washington
- Seattle, Washington
- Yakima, Washington
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia. | |||
Official Title ICMJE | A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients. | |||
Brief Summary | The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make decisions or problem solve. The study is also designed to assess if there is a difference in cognitive function between fibromyalgia patients and matched control subjects. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Fibromyalgia | |||
Intervention ICMJE | Drug: Esreboxetine
Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing | |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 89 | |||
Original Estimated Enrollment ICMJE | 80 | |||
Actual Study Completion Date ICMJE | June 2009 | |||
Actual Primary Completion Date | June 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00752505 | |||
Other Study ID Numbers ICMJE | A6061061 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |